Microphysiological systems (MPS) hold promise for improving therapeutic drug approval rates by providing more physiological, human-based, in vitro assays for preclinical drug development activities compared to traditional in vitro and animal models. Here, we first summarize why MPSs are needed in pharmaceutical development, and examine how MPS technologies can be utilized to improve preclinical efforts. We then provide the perspective that the full impact of MPS technologies will be realized only when robust approaches for in vitro–in vivo (MPS-to-human) translation are developed and utilized, and explain how the burgeoning field of quantitative systems pharmacology (QSP) can fill that need.

中文翻译：

---

通过体外-体内翻译 最大程度地提高微生理系统的影响

与传统的体外和动物模型相比，微生理系统（MPS）通过为临床前药物开发活动提供更多基于人类的生理学体外试验，有望提高治疗药物的批准率。在这里，我们首先总结为什么在药物开发中需要MPS，并研究如何利用MPS技术改善临床前工作。然后，我们提供了这样的观点，即只有开发和利用可靠的体外-体内（MPS到人）翻译方法，才能实现MPS技术的全部影响，并说明如何在定量系统药理学（QSP）领域迅速发展）就可以满足需求。